$MDCX News

Last published 2d ago

2d agoMDCXMEDICUS PHARMA THIRD QUARTER 2026 FINANCIAL PERFORMANCE AND BUSINESS UPDATE - MEDICUS PHARMA LTDEarnings Call TranscriptsWelcome to the Medicus Pharma 3rd Quarter 2026 Financial Performance and Business Update Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by
2d agoMDCXMedicus Pharma to Highlight Rationale for CD228V Co-Development and License AgreementACCESS NewswireMedicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today outlined key highlights for its third quarter 2026 financial performance and business update conference call at 11:30 a.m. Eastern Time today, following the filing of it ...
5d agoMDCXMedicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateACCESS NewswireMedicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today reported financial results for the three and nine months ended September 30, 2026, and provided a business update highlighting capital efficient strategic, clinical and ...
6d agoMDCXMedicus Pharma to Present at BIO-Europe 2026GlobeNewswirePHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and
1w agoMDCXMedicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026GlobeNewswirePHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical
1w agoMDCXMedicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent FinancingGlobeNewswirePHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and
2w agoMDCXMedicus Pharma to Present at BioFuture and Global Biotechnology SummitGlobeNewswirePHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and
2w agoMDCXMedicus Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswirePHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and
1mo agoMDCXMedicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term ValueGlobeNewswirePHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and
1mo agoMDCXMedicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory AssessmentGlobeNewswirePHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and
2mo agoMDCXMedicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development DoseGlobeNewswirePHILADELPHIA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and
2mo agoMDCXMedicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology CompanyGlobeNewswirePHILADELPHIA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision-guided biotech/life sciences company focused on advancing the clinical
3mo agoMDCXMedicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateACCESS NewswireCompany Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion
3mo agoMDCXMedicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United KingdomGlobeNewswirePHILADELPHIA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
3mo agoMDCXMedicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with EndometriosisGlobeNewswirePHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
3mo agoMDCXMedicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin SyndromeGlobeNewswirePHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
3mo agoMDCXMedicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary RetentionGlobeNewswirePHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
4mo agoMDCXMedicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026GlobeNewswirePHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
4mo agoMDCXMedicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin SyndromeGlobeNewswirePHILADELPHIA, June 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and
5mo agoMDCXMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome ProgramGlobeNewswirePHILADELPHIA, June 11, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and
5mo agoMDCXMedicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European SubmissionGlobeNewswirePHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and
5mo agoMDCXMedicus Pharma Advances SkinJect® into Registrational Development for Gorlin SyndromeGlobeNewswirePHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and
5mo agoMDCXMedicus Pharma Announces $22 Million Non-Dilutive FinancingGlobeNewswirePHILADELPHIA, May 28, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and
6mo agoMDCXMedicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswirePHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
6mo agoMDCXMedicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-ResponseGlobeNewswirePHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
6mo agoMDCXMedicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol HillGlobeNewswirePHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
6mo agoMDCXMedicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin SyndromeGlobeNewswirePHILADELPHIA, April 17, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
7mo agoMDCXMedicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone SuppressionGlobeNewswirePHILADELPHIA, April 15, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
7mo agoMDCXMedicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary RetentionGlobeNewswirePHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
7mo agoMDCXMedicus Pharma Ltd Clarifies Positive SkinJect Phase 2 DatasetGlobeNewswirePHILADELPHIA, April 01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
7mo agoMDCXMedicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response RateGlobeNewswirePHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
7mo agoMDCXMedicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development PlanGlobeNewswirePHILADELPHIA, March 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
7mo agoMDCXMedicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate UpdateACCESS NewswireAdvances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 ProgramsPHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. ("Medicus"
7mo agoMDCXMedicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research AnalystACCESS NewswirePhase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.PHILADELPHIA, PA / ACCESS Newswire / March 18,
8mo agoMDCXMedicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26GlobeNewswirePhase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE
8mo agoMDCXMedicus Pharma Ltd. To Participate In The Longwood Miami CEO ForumACCESS NewswireDr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development StrategyPHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medicus Pharma Ltd.
8mo agoMDCXMedicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ DatasetGlobeNewswirePHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
8mo agoMDCXMedicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg CohortGlobeNewswirePHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
8mo agoMDCXMedicus Pharma To Participate in the 38th Annual Roth ConferenceGlobeNewswirePHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of
9mo agoMDCXMedicus Pharma on Bloomberg WorldACCESS NewswireDr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt MillerPHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. , a
9mo agoMDCXMedicus Pharma Receives FDA "Study May Proceed" Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular RiskGlobeNewswirePHILADELPHIA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical
9mo agoMDCXMedicus Pharma Marks Nasdaq Anniversary With Opening Bell CeremonyACCESS NewswirePHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. , a precision guided biotech/life sciences company focused on advancing the clinical
9mo agoMDCXMedicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development ProfileGlobeNewswireAmendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute
9mo agoMDCXMedicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026GlobeNewswirePHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical
10mo agoMDCXMedicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in WomenGlobeNewswirePHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical
10mo agoMDCXMedicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness AcceleratesGlobeNewswirePHILADELPHIA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical
10mo agoMDCXMedicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics PlatformACCESS NewswireThe engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary retention
11mo agoMDCXMedicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the SkinGlobeNewswireTHE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026 PHILADELPHIA, Dec.
11mo agoMDCXMedicus Pharma Ltd. Enters Into $5.1 Million Warrant InducementACCESS NewswireMaxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. ,
11mo agoMDCXMedicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as PresidentACCESS NewswireCarolyn Bonner Succeeds James Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus Pharma Ltd.